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Introduction: The therapeutic potential of mesenchymal stem cells (MSCs) for traumatic brain injury (TBI) is attractive.
Conducting systematic review and meta-analyses based on data from animal studies can be used to inform clinical trial
design. To conduct a systematic review and meta-analysis to (i) systematically review the literatures describing
the effect of MSCs therapy in animal models of TBI, (ii) determine the estimated effect size of functional locomotor
recovery after experimental TBI, and (iii) to provide empirical evidence of biological factors associated with greater efficacy.
Methods: We conducted a systematic search of PubMed, EMBASE, and Web of Science and hand searched
related references. Studies were selected if they reported the efficacy of MSCs in animal models of TBI. Two
investigators independently assessed the identified studies. We extracted the details of individual study characteristics
from each publication, assessed study quality, evaluated the effect sizes of MSCs treatment, and performed stratified
meta-analysis and meta-regression, to assess the influence of study design on the estimated effect size. The presence
of small effect sizes was investigated using funnel plots and Egger’s tests.
Results: Twenty-eight eligible controlled studies were identified. The study quality was modest. Between-study
heterogeneity was large. Meta-analysis showed that MSCs exert statistically significant positive effects on sensorimotor
and neurological motor function. For sensorimotor function, maximum effect size in studies with a quality score of 5
was found in the weight-drop impact injury TBI model established in male SD rats, to which syngeneic umbilical
cord-derived MSCs intracerebrally at cell dose of (1–5) × 106 was administered r 6 hours following TBI, using ketamine
as anesthetic agent. For neurological motor function, effect size was maximum for studies with a quality score of
5, in which the weight-drop impact injury TBI models of the female Wistar rats were adopted, with administration
syngeneic bone marrow-derived MSCs intravenously at cell dose of 5 × 106 at 2 months after TBI, using sevofluorane
as anesthetic agent.
Conclusions: We conclude that MSCs therapy may improve locomotor recovery after TBI. However, additional
well-designed and well-reported animal studies are needed to guide further clinical studies.Introduction
Traumatic brain injury (TBI) is the leading cause of
long-term disability in children and young adults world-
wide [1]. In the USA alone, TBI leaves 80,000 individuals
with permanent disabilities and costs more than US$77
billion on average per year [2]. One of the most preva-
lent and debilitating features in survivors of TBI is* Correspondence: ericwangzhe@126.com
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unless otherwise stated.motor dysfunction [3]. TBI survivors with motor dys-
functions tend to walk slower, take smaller steps and
strides, show greater mediolateral sway, and may step
higher to clear obstacles [4]. However, there is currently
no effective strategy to treat the functional sequelae as-
sociated with TBI, except for palliative treatment or sur-
gery in some cases, as well as neuro-rehabilitation [5].
At present, the beneficial effects of mesenchymal stem
cell (MSC)-based therapy for acute neurological injuries
in animal models, like TBI [6], have drawn more and
more attention. MSCs are multipotent, fibroblast-like
cells that were first found in the stromal compartmenthis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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leagues [7]. In addition to bone marrow, similar popula-
tions have been identified in other adult and fetal tissues,
such as bone and adipose tissue, skeletal muscle, teeth,
pancreas, lung, liver, amniotic fluid, endometrial polyps,
menstrual blood, cord blood, and umbilical cord tissues
[3,8-11]. In addition to the ability of multilineage cell type
differentiation, MSCs have recently been shown to exhibit
other coveted properties such as anti-inflammatory, immu-
nomodulatory, anti-apoptotic, trophic, and angiogenic
effects [12]. Moreover, MSCs have high potency in the
modulation of the body’s immune system [13], the para-
crine secretion of multiple growth factors and cytokines
[14], and migration to the diseased site of the body [15].
Furthermore, MSCs present relative ease of isolation, ef-
ficient ex vivo expansion, lack of ethical concerns, and
acceptable safety [16-19]. All of these features make
MSCs an ideal therapeutic regimen to treat various in-
juries including stroke [20,21], myocardial infarction
[22], acute lung injury [23], and TBI [24]. Several lines
of studies have investigated the efficacy of MSCs in TBI
patients [25,26]. However, they have mainly focused on
issues of safety and feasibility, which was underpowered
due to lack of proper randomized control. By contrast,
an increasing number of rodent studies have investigated
the efficacy of MSCs on neurological recovery, a relevant
clinical outcome that is considered pivotal among TBI pa-
tients [27-29].
Although MSCs have been acknowledged as a desir-
able candidate in treating TBI-associated neurological
deficits in animal models, further clinical trials are
needed. In this regard, systematic reviews and meta-
analyses on animal studies can allow such decisions to
be made based on the entirety of existing evidence that
is synthesized in an unbiased manner [30]. Importantly,
systematic reviews and meta-analyses of animal studies
can offer a sensible and rational approach to assess the
translational potential of promising experimental inter-
ventions before decisions are made to proceed with clin-
ical trials. However, to our knowledge, a systemic review
and meta-analysis of the therapeutic efficacy of MSCs on
TBI has not so far been performed in experimental ani-
mal studies. Therefore, in this investigation we intended
to conduct a systematic review and meta-analysis to de-
termine whether the evidence from animal experiments
was in favor of MSCs, in terms of mitigating the neuro-
behavioral outcome in TBI animal models, and to yield
information used to inform animal and clinical studies
on MSC intervention in TBI.Methods
The study protocol accomplished in advance of any data
collection is available online [31]. The methods andstatistical evaluation approach are described in greater
detail in this study protocol.
Search strategy
We searched three electronic databases (PubMed,
EMBASE, and Web of Science; 30 November 2014) for
controlled studies reporting the efficacy of MSCs in an
in vivo animal model of TBI. The search terms, applied
with various Boolean operators, are summarized in Table
S1 in Additional file 1 and were kept broad to capture
all potentially relevant articles.
Searches of the databases using these search terms
were preformed independently by two individuals. The
bibliographies of relevant articles were used to identify
further relevant publications. Abstracts were independ-
ently screened by two reviewers to identify studies meet-
ing our inclusion criteria (see below), with differences
resolved by discussion with a third reviewer.
Eligibility criteria
Types of studies
We included controlled comparative studies (randomized,
quasi-randomized, and nonrandomized) assessing the effi-
cacy of MSC therapy in preclinical models of TBI. No lan-
guage, publication date, or publication status restrictions
were imposed.
Preclinical animal models
Four widely-used TBI animal models (fluid percussion
injury, controlled cortical impact injury, weight-drop im-
pact acceleration injury, and blast injury) were enrolled
in this study [32], and these models can mimic at least
part of the diverse pathophysiological aspects of TBI. Be-
cause our proposed future clinical trials will focus on
adults with TBI, neonatal animal models of TBI were ex-
cluded due to the existence of possible differences in
underlying mechanisms and response to a specific treat-
ment between the two groups.
Interventions
The preclinical intervention group included animals
from studies that examine MSC types (xenogeneic, syn-
geneic, or allogeneic cells from any tissue source).
MSCs were defined using minimal criteria set out in
the International Society for Cellular Therapy consen-
sus statement [33]. MSCs must be administered during
or following the induction of experimental TBI. Experi-
ments using pretreatment of MSCs were excluded since
they are clinically relevant for the prevention, but not
for the treatment, of human TBI. In order to focus on
nonmanipulated MSCs, studies using differentiated
MSCs (for example, MSCs that had been differentiated
into endothelial cells) or MSCs engineered to overex-
press or underexpress particular genes, or studies using
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excluded. However, MSCs that had been labeled or
transfected with cellular markers intended for tracing
and imaging (green fluorescent protein, lacZ, bromo-
deoxyuridine, superparamagnetic iron oxide particles,
and so forth) were included. Administration of MSCs
accompanied by co-culture or concomitant injection of
other cell types or co-treatment of any adjuvant prod-
ucts (for example, matrices, scaffolding) were excluded.
Control interventions consisted of placebo (saline, cul-
ture medium, or similar vehicle).
Neurobehavioral outcome
We included all methods measuring motor function, in-
cluding sensorimotor function and neurological motor
function, such as the modified Neurological Severity
Score, Neurological Severity Score, foot fault tests, the
Rotarod test, the behavior test, motor function scores,
and so forth [34-36], in which a baseline of normal or
pre-TBI function could be clearly established. In order
to be aggregated in the meta-analysis, outcomes must be
presented as neurobehavioral outcomes. Moreover, the
exact animal numbers in each group, the mean effect
size, and variance of the consequences are supposed to
be reported. Disagreements between investigators were
resolved by consensus after discussion.
Data extraction
The following items were independently extracted by
two investigators from each included study: reference
details (publication year and name); recipient animal (rat
strain and sex); TBI (traumatic model); MSCs (donor
species and tissue source); intervention regime (time
from TBI to intervention, administration route, and
number of injections); type of anesthetic agent; time of
outcome assessment; and motor function measures.
We extracted details of individual study characteristics
from each publication, and where a single publication
reported more than one experiment these data were ex-
tracted and treated as independent experiments. When
neurobehavioral tests were performed serially, only data
for the final time point were extracted.
In cases of missing data, we contacted the authors to
request further information, clarification, or missing
data. If data were expressed only graphically, numerical
values were requested from the authors; if a response
was not received, digital ruler software was applied to
estimate numerical values from the graphs. If required
data were not presented or obtained, then the study was
eliminated from the detailed analysis.
Methodological quality of studies
The methodological quality of individual studies was assessed
based on a checklist modified from the CollaborativeApproach to Meta-Analysis and Review of Animal
Data from Experimental Studies (CAMARADES) as
described previously with minor modification [37,38].
The checklist was comprised of 10 items: (1) peer review
publication; (2) presence of randomization; (3) assessment
of dose–response relationship; (4) blinded assessment of
behavioral outcome; (5) monitoring of physiological pa-
rameters temperature; (6) sample size calculation; (7) state-
ment of compliance with regulatory requirements; (8) use
of other alternative anesthetics but not ketamine (because
of its marked neuroprotective activity); (9) statement of
potential conflicts of interest; and (10) use of accurate/
suitable/adequate animal models. One point was given for
evidence of each quality criterion.
Statistical analysis
In line with the Cochrane Handbook for Systematic Reviews
of Interventions [39], the global estimated effect of MSCs
on motor outcome was determined by calculating the
standardized mean difference (equal to the difference in
mean outcome between groups divided by the standard
deviation of outcomes among participants, reported in
units of standard deviation) and 95% confidence intervals
(CIs) using a random-effects model to avoid heterogeneity
[38]. The standardized mean difference is used as a sum-
mary statistic in meta-analyses when studies assess the
same outcome but measure the outcome in a variety of
ways (for example, multiple studies measuring depression
but using different psychometric scales). Within-study
and between-study variation or heterogeneity was assessed
using Cochran’s Q statistic [40,41], with a significant Q
statistic (P <0.10) indicating heterogeneity among studies.
Heterogeneity was also assessed using the I2 metric, with
higher values denoting a greater degree of heterogeneity
(0 to 40%, little heterogeneity; 30 to 60%, moderate het-
erogeneity; 50 to 90%, substantial heterogeneity; 75 to
100%, considerable heterogeneity). I2 ≤ 50% indicates ac-
ceptable heterogeneity among studies [39]. For studies
comparing different doses and/or times of drug adminis-
tration with a single control group, we compared control
group data with pooled data from all experimental groups.
Stratified meta-analysis was used to explore the influ-
ence of the potential factors on estimated effect size [42].
Differences in mean effect sizes were assessed partitioning
heterogeneity using the χ2 distribution with n – 1 degrees
of freedom (df). Bonferroni correction was used to adjust
significance levels for multiple comparisons:
Declared significance
¼ 1 – 1 – denoted significanceð Þ 1 = number of comparisonsð Þ
This correction yielded critical P values of 0.0024 for
sensorimotor function and 0.0057 for neurological
motor function [43,44].
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tential sources of heterogeneity, as described in a previ-
ous study [45]. The presence of small effect sizes was
investigated using funnel plots and Egger’s tests. For
Egger’s tests, P <0.10 was considered to indicate the
presence of small effect sizes [40].
All statistical analyses were performed using Review
Manager (version 5.3) The Nordic Cochrane Centre, The
Cochrane Collaboration, Copenhagen, Denmark and Stata
software (version 12.1) StataCorp LP, Texas, USA.Results
Study selection
Our review identified 924 publications, of which 28 met our
prespecified inclusion criteria [5,6,12,46-70]. Among these,
four studies assessing functional neurological were excluded
due to inadequate data necessary for calculating the sum-
mary effect of measured outcome. Our meta-analysis was
thus conducted based on 24 publications, which include 37
comparisons of sensorimotor function and 15 comparisons
of neurological motor function (Figure 1).Figure 1 Flow diagram of study search process. A total of 28 studies were
24 studies only, with four studies excluded due to inadequate reporting of daDescription of studies
The median year of publication was 2011 (range, 2001
to 2014). Bone marrow (22 studies) was the most fre-
quently used MSC tissue source, followed by umbilical
cord (four studies). Sprague–Dawley and Wistar rats
were the most frequently used rodent strains as recipi-
ents, C57Bl/6 mice as the recipient rodent strain was ob-
served in four studies [53,60,62,63], and one study failed
to report the recipient rodent strains [50]. Controlled
cortical impact injury (17 studies) and weight-drop im-
pact injury (eight studies) were the most frequently used
animal models of TBI. The median time interval be-
tween TBI induction and MSC intervention was
24 hours, with a longest interval of 2 months. Intraven-
ous injection (19 studies) was the most frequently re-
ported administration route (median total dose, 2 × 106
MSCs; range, 1.5 × 105 to 2 × 1012).
The Neurological Severity Score or modified Neuro-
logical Severity Score, as the gross neurological deficit
score for sensorimotor function, and the Rotarod test were
the most frequently used methods to determine neuro-
logical motor function (Table S2 in Additional file 1).identified for systematic review, and the meta-analysis was based on
ta requisite for calculating the summary effect of measured outcome.
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Overall, the median quality score was 6 (interquartile
range, 5 to 7), with scores ranging from 3 to 9. Seven
studies did not report randomization of animals into
treatment groups, four study assessed dose–response re-
lationships, and 11 studies failed to state that outcome
measures were made by experimenters who were blind
to animal treatment. Only one study described calcula-
tion of the necessary sample size. Seventeen studies
stated the compliance with regulatory requirements.
Moreover, 13 studies contained a statement of potential
conflicts of interest (Table S3 in Additional file 1).
Overall efficacy
Efficacy of MSCs on sensorimotor function was evaluated
based on measurement of functional outcome in 22 in-
cluded trials and 37 parallel comparison groups, which in-
volved 657 animals that underwent evaluation for modified
Neurological Severity Score, Neurological Severity Score,
foot fault tests, elevated body swing test, forelimb akinesia,
paw-grasp test, or beam walk tests. The global estimated ef-
fect of MSCs was −1.86 (95% CI: −2.27 to −1.44, P
<0.0001), with significant heterogeneity among studies (χ2
= 153.56, df = 36 (P <0.0001), I2 = 77%; Figure 2a). For
neurological motor function, in 15 comparisons of nine in-
cluded studies involving 222 animals – measured using the
Rotarod test, the behavior test, and motor function scores
– the global estimated effect of MSCs was 1.36 (95% CI:
0.76 to 1.96, P <0.0001), with significant heterogeneity
among studies (χ2 = 50.52, df = 14 (P <0.0001), I2 = 72%;
Figure 2b). The pooled analysis indicates that animals in
the treatment group showed significantly improved sensori-
motor function and neurological motor function compared
with animals in the control group (Figure 2a,b).Figure 2 Effects of mesenchymal stem cells on sensorimotor function and n
motor function. Horizontal lines, mean estimated effect size and 95% confide
pooled estimated effect size.Stratified meta-analysis
In stratified meta-analysis, the impact of study quality,
type of TBI model, MSC graft type, MSC tissue source,
MSC dose, time interval between TBI induction and
MSC administration, route of administration, recipient
rodents’ sex, recipient rodents’ strain, and anesthetic agent
on the effect sizes of sensorimotor and neurological motor
function was examined.
For sensorimotor function, no significant differences
in effect sizes were unveiled relative to the study quality
score (χ2 = 1.83, df = 6, P = 0.93), MSC dose (χ2 = 2.75,
df = 3, P = 0.43), anesthetic agents (χ2 = 4.53, df = 5, P =
0.48), types of TBI model (χ2 = 0.31, df = 1, P = 0.58),
route of administration (χ2 = 0.43, df = 1, P = 0.51), time
from TBI to intervention (χ2 = 11.26, df = 6, P = 0.08),
MSC donor species (χ2 = 1.22, df = 2, P = 0.54), recipient
rodents’ sex (χ2 = 3.47, df = 3, P =0.32), MSC graft type
(χ2 = 0.04, df = 1, P = 0.84), MSC tissue source (χ2 = 4.48,
df = 3, P = 0.21), and recipient rodents’ strain (χ2 = 8.75,
df = 4, P = 0.07). However, the effect size was maximum
for studies including a quality score of 5 (−2.99, 95%
CI: −3.79 to −0.79; Figure 3a), the weight-drop impact
injury models (−1.92, 95% CI: − 2.39 to −1.45; Figure 3b),
syngeneic grafts (−1.90, 95% CI: −2.49 to −1.32; Figure 3c),
umbilical cord-derived MSCs (−3.02, 95% CI: −5.18
to −0.85; Figure 3d), MSCs at a (1 to 5) × 106 cell
dose (−2.03, 95% CI: −2.48 to −1.58; Figure 3e), 6 hours
following TBI (−2.86, 95% CI: −4.27 to −1.46; Figure 3f), in-
tracerebral administration (−2.04, 95% CI: −2.39 to −1.68;
Figure 3g), male rodents (−2.09, 95% CI: −2.63 to −1.55;
Figure 3h), Sprague–Dawley rats (−2.28, 95% CI: −2.79
to −1.77; Figure 3i), and ketamine as an anesthetic
agent (4.02, 95% CI: 2.38 to 5.66; Figure 3j) (Table S4.1
in Additional file 1).eurological motor function. (a) Sensorimotor function. (b) Neurological





Figure 3 (See legend on next page.)
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Figure 3 Estimated effect size for sensorimotor function. Estimated effect size for sensorimotor function stratified by (a) quality of study, (b) type of
traumatic brain injury (TBI) model, (c) mesenchymal stem cell (MSC) graft type, (d) MSC tissue source, (e) MSC dose, (f) time from TBI to administration,
(g) administration route, (h) recipient rodents’ sex, (i) recipient rodents’ strain, and (j) anesthetic agents. Grey bands, 95% confidence interval for the
global estimated effect size. CCI, controlled cortical impact; SD, Sprague–Dawley.
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in effect sizes were observed in terms of the study qual-
ity score (χ2 = 31.91, df = 4, P <0.0001), anesthetic agent
(χ2 = 23.80, df = 3, P <0.0001), time from TBI to inter-
vention (χ2 = 18.69, df = 2, P <0.0001), MSC graft type
(χ2 = 9.70, df = 1, P = 0.002), type of TBI model (χ2 = 25.96,
df = 2, P <0.0001), and MSC dose (χ2 = 21.70, df = 3,
P <0.0001), No significant differences in effect sizes were
found relative to route of administration (χ2 = 0.61, df = 1,
P = 0.43), recipient rodents’ sex (χ2 = 9.11, df = 2, P = 0.01),
MSC tissue source (χ2 = 3.23, df = 1, P = 0.07), and recipi-
ent rodents’ strain (χ2 = 2.80, df = 1, P = 0.09). Moreover,
the effect size was maximum for studies with a quality
score of 5 (4.02, 95% CI: 2.38 to 5.66; Figure 4a), using the
weight-drop impact injury models (4.02, 95% CI: 2.38 to
5.66; Figure 4b), syngeneic grafts (2.50, 95% CI: 1.46 to
3.54; Figure 4c), bone marrow-derived MSCs (1.49, 95%
CI: 0.82 to 2.16; Figure 4d), MSCs at 5 × 106 cell dose
(4.02, 95% CI: 2.38 to 5.66; Figure 4e), 2 months after TBI
(4.02, 95% CI: 2.38 to 5.66; Figure 4f), intravenous admin-
istration (1.62, 95% CI: 0.88 to 2.37; Figure 4g), female ro-
dents (3.07, 95% CI: 1.80 to 4.35; Figure 4h), Wistar rats
(1.90, 95% CI: 0.92 to 2.88; Figure 4i), and sevofluorane as
an anesthetic agent (4.02, 95% CI: 2.38 to 5.66; Figure 4j)
(Table S4.2 in Additional file 1).Meta-regression analyses
In principle, meta-regression allows the effects of mul-
tiple factors to be investigated simultaneously. In order
to explore heterogeneity among studies, meta-regression
was further conducted. For sensorimotor function, qual-
ity of study, type of TBI model, MSC graft type, MSC
tissue source, MSC dose, route of administration, and
recipient rodents’ sex were the significant sources of
heterogeneity for the group (P <0.05) (Table S4.1 in
Additional file 1). For neurological motor function,
quality of study, type of TBI model, MSC graft type, route
of administration, recipient rodents’ strain, and anesthetic
agent were the significant sources of heterogeneity for the
group (P <0.05) (Table S4.2 in Additional file 1).Publication bias
Finally, we sought to identify the presence of small study
effects, which may contribute to publication bias. Asym-
metry in funnel plots of sensorimotor function indicated
the presence of publication bias (Figure 5a; Eggerregression, P <0.0001). For neurological motor function,
asymmetry in funnel plots occurred, which indicated
existence of publication bias (Figure 5b; Egger regres-
sion, P <0.0001).
Discussion
It has been argued forcefully that it is necessary to con-
duct systematic reviews and meta-analyses on animal
experiments aimed at modeling clinically relevant prob-
lems [71-73], since many treatments that lack any evi-
dence of beneficial effect are currently being offered to
vulnerable groups of patients [74,75]. Moreover, system-
atic reviews and meta-analyses of animal experiments
not only allow for a more objective appraisal of the re-
search evidence than is allowed by the traditional narra-
tive reviews more commonly associated with animal
research, but also offer a sensible and rational approach
to assess the translational potential of promising experi-
mental interventions before decisions are made to
proceed with clinical trials [76].
The present review is, to our knowledge, the first at-
tempt to systematically collect all available evidence and
critically assess and quantify the efficacy of MSCs in ani-
mal models of TBI. From the results of our random-
effects meta-analysis, we conclude that MSCs might be
beneficial in treating experimental TBI in terms of im-
proving sensorimotor and neurological motor function,
indicating that MSCs might be a potentially new candi-
date for neuroprotective activity in the context of TBI.
However, this is a meta-analysis of the efficacy of MSCs
in animal models of TBI, based on 24 studies only. In
addition, the significant statistical heterogeneity and the
low quality of many studies included in this review re-
duce bias for MSCs having a substantial beneficial effect
on locomotor recovery in animal models of TBI. Simi-
larly, our previous investigations have shown that statins
and erythropoietin were also proven to have neuropro-
tective properties for animal TBI models, although there
was significant statistical heterogeneity and a low quality
for many studies included in the previous systematic re-
views [30,76].
As anticipated, significant heterogeneity in treat-
ment effect was found between study groups. This
finding is typical for systematic reviews in animal
studies and validates our choice of a random-effects
model, and our summary estimates should be consid-











Figure 4 Estimated effect size for neurological motor function. Estimated effect size for neurological motor function stratified by (a) quality of
study, (b) type of traumatic brain injury (TBI) model, (c) mesenchymal stem cell (MSC) graft type, (d) MSC tissue source, (e) MSC dose, (f) time
from TBI to administration, (g) administration route, (i) recipient rodents’ sex, (h) recipient rodents’ strain, and (j) anesthetic agents. Grey bands,
95% confidence interval for the global estimated effect size. CCI, controlled cortical impact; FPI, fluid percussion injury; SD, Sprague–Dawley.
Peng et al. Stem Cell Research & Therapy  (2015) 6:47 Page 8 of 13estimate of a single true efficacy. The main reasons for
heterogeneity in this present review were attributed to
the limited number of studies and the small sample
sizes within those studies. Another important contri-
bution to this heterogeneity may be the low quality of
studies and potential bias of the studies selected foranalysis [77]. Moreover, heterogeneity not explained
by random error is a consequence of experimental di-
versity between studies [78].
Next, we performed meta-regression analysis to exam-
ine potential sources of heterogeneity. Our results sug-
gested that the effect of MSCs on sensorimotor function
Figure 5 Begg’s funnel plot. (a) Sensorimotor function. (b) Neurological motor function. There was evidence of small study effects (Egger’s test
bias coefficient: −4.9792, 95% confidence interval (CI): −6.729 to −3.229, P <0.0001; and 5.6357, 95% CI: 3.6827 to 7.5886, P <0.0001). s.e., standard
error; SMD, standardized mean difference.
Peng et al. Stem Cell Research & Therapy  (2015) 6:47 Page 9 of 13and neurological motor function could be associated
with some explanatory variables. However, it is import-
ant to keep in mind that such analyses are entirely ob-
servational by nature and not based on randomized
comparisons. Hence, they suffer from the usual limita-
tions of any observational investigation, including bias
through confounding by other potential explanatory var-
iables. In addition, we assessed the methodological qual-
ity of studies in accordance with previously described
standards for preclinical development of neuroprotective
drugs with minor modifications [37]. Overall, we found
that the quality of the included studies was modest be-
cause many failed to report sample size calculation, to
report blinded assessment of outcome, or to determine a
dose–response relationship, which are important issues
generally required in clinical studies [79]. The global esti-
mated effect of MSCs on TBI may therefore beoverestimated due to the low quality of studies. This
phenomenon is not limited to our investigation; in other
systematic reviews of controlled trials in animal models
[73,80,81], the statistical heterogeneity between compari-
sons for all outcomes is also evident, and/or the overall
methodological quality of included studies was also poor.
Publication bias is known to be a major problem in the
reporting of clinical trials. Here, we showed that publication
bias is prevalent in reports of laboratory-based research in
animal models of TBI investigating the effect of MSCs on
sensorimotor function recovery. Combined with our previ-
ous investigations [30,76] and other studies [73,80], it is
unlikely that the publication bias reported here is limited to
the effect of MSC efficacy on sensorimotor function recov-
ery and is likely to be prevalent in experimental TBI models.
Our study has several limitations, which have also been
observed in previous systematic reviews of animal studies
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fort to identify all relevant studies, only data from pub-
lished studies were successfully included in our analyses. It
is worth mentioning that, at least with regards to motor
outcome, there was evidence of a publication bias in favor
of studies with large effect sizes. Our analysis did not take
unpublished data into account, so the overall effect size
might be overstated in our results. Secondly, previous cu-
mulative meta-analyses of in vivo data suggested that the
effect estimates become stable if approximately 1,500 ani-
mals have been included [84]. The current meta-analysis
included data from only 879 animals, which limited confi-
dence in effect estimates. Thirdly, we limited our analysis
to neurobehavioral outcomes following TBI, largely due to
insufficient data regarding histopathology such as the le-
sion volume. However, functional outcome, in combin-
ation with histopathology, may be just as important in
terms of assessing potential neuroprotective drugs [22],
and this is worthy of further exploration. Fourthly, we
present a series of univariate analyses. Multivariate meta-
regression or stepwise partitioning of heterogeneity might
provide more robust insights, but these techniques have
not been well established. Similarly, for continuous vari-
ables, the meta-regressions reported here assumed a linear
relationship between the independent and dependent vari-
ables, which probably represented an oversimplification, at
least for some independent variables [85]. Fifthly, extract-
ing multiple pieces of information from a single publica-
tion has the potential to introduce bias into systematic
reviews because we have observed the experiments of
others rather than conducted experiments of our own, and
this observational research should be considered as
hypothesis-generating only [85]. Lastly, a variety of differ-
ent metrics were used (for example, pressure, weight, vel-
ocity) to evaluate TBI severity, and no studies specified the
degree of severity (for example, mild, moderate, or severe).
The results of different studies could therefore be more ac-
curately compared if injury severity is reported in a con-
sistent manner. Importantly, although we found that MSC
treatment can have beneficial effects in animal models of
TBI, the majority of studies used only controlled cortical
impact or weight-drop impact injury models. Any animal
model may not fully recapitulate all aspects of secondary
injury development observed in humans with TBI [32],
thereby limiting the extent to which this experimental re-
search translates to a clinical population.
In addition, other types of stem cells have also been
used to treat TBI animals, such as neural progenitor
cells, neural stem cells, and embryonic stem cells. Im-
provement of sensorimotor and neurological motor
function has also been observed after transplantation of
neural stem cells directly to the cortex below the injury
cavity or the cortex–hippocampus interface in controlled
cortical impact-injured animals, where cells also showedphenotypic evidence of neuronal differentiation [34,86].
Other authors have also shown that transplantation of
neural progenitor cells in the acute and chronic post-
traumatic period following TBI could enhance motor
and cognitive recovery, and promote survival, migration,
and neuronal differentiation. Embryonic stem cell trans-
plantation has also demonstrated neurological motor
function improvements following lateral fluid percussion
brain injury in Sprague–Dawley rats, but may cause tu-
mors, which raises serious safety concerns about the use
of such cells in human [87].
As mentioned in our previous systematic reviews
[30,76], to improve the transition from animal experi-
ments to human clinical trials, researchers are strongly
recommended to consult and follow the Animals in Re-
search: Reporting In Vivo Experiments (ARRIVE) guide-
lines [88,89] when designing studies and reporting full
methodological details to allow others to reproduce and
validate their results and also to enable more accurate
reviews and meta-analyses. In addition, other short-term
outcomes such as lesion volume, brain edema, blood–
brain barrier permeability, as well as long-term disability
including cognitive, emotional, and behavioral problems
should also be examined. Moreover, additional appropri-
ate and standardized TBI models are needed to evaluate
the impact of promising pharmacological interventions
on TBI.
Conclusions
Our present investigation suggests that MSCs may have
beneficial effect on locomotor recovery in animal models
of TBI. The results, however, should be interpreted in
light of the known limitations in animal experimental
design and methodological quality.
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